Oprozomib, Pomalidomide (cas 19171-19-8), and dexamethasone in patients with relapsed and/or refractory multiple myeloma

Add time:07/25/2019    Source:sciencedirect.com

PurposeThis phase 1b study evaluated oprozomib, an oral proteasome inhibitor, plus pomalidomide-dexamethasone in relapsed/refractory multiple myeloma (RRMM).

We also recommend Trading Suppliers and Manufacturers of Pomalidomide (cas 19171-19-8). Pls Click Website Link as below: cas 19171-19-8 suppliers

Prev:Design, synthesis and biological assessment of novel N-substituted 3-(phthalimidin-2-yl)-2,6-dioxopiperidines and 3-substituted 2,6-dioxopiperidines for TNF-α inhibitory activity
Next:Rearrangement of carbocations derived from 1,8-bis(dimethylamino)naphthyl-2-methanols into 4-R-1,1,3-trimethyl-2,3-dihydroperimidinium salts)